);
Contact

News

Posted on
LinkedIn Post 1
October 2025

All eyes on Fertiga in Women’s Health Week Europe 2025!

We’re thrilled to announce that Fertiga is selected to pitch at the Med Device & Therapeutics Innovation Showcase during Women’s Health Week Europe 2025 on 17 October!

Our presentation in the ‘Clinical, Diagnostic, or Treatment-based’ category will spotlight how Fertiga is redefining fertility care through science and innovation. A fantastic opportunity to connect with investors, pharma leaders, and health systems shaping the future of women’s health. 🌍💡

Posted on
LinkedIn Post 1
October 2025

Fertiga is attending BioJapan 2025 and Japan Society of Assisted Reproduction!

We’re proud to share that Elien Van Hecke, CCO at Fertiga, will be present in Yokohama at BioJapan 2025 (October 8-10) to connect with partners, discuss the future of fertility biotech, and showcase our pioneering work in IVF innovation. Looking forward to inspiring conversations and new collaborations! ✨

Nontheless, Fertiga is honored to be present at the Japan Society of Assisted Reproduction. Elien Van Hecke will engage with the reproductive medicine community and highlight our commitment to advancing fertility biotech and IVF innovation. Looking forward to meaningful exchanges and future collaborations!🌍

Posted on
LinkedIn Post 1
July 2025

Fertiga at the 41st ESHRE Annual Meeting in Paris, France

Fertiga, in collaboration with Brussels IVF and Merck KGaA, Darmstadt, Germany, has announced ground-breaking results from the AURORA-REC study on gene expression in ICSI patients treated with r-hFSH or r-hFSH & r-hLH. During AURORA-REC study we evaluated the differences in cumulus cell gene expression between two types of ovarian stimulation and proved that gene-based algorithms can predict live birth in these patient groups:

  • the accuracy achieved for women stimulated with r-hFSH was 69%
  • the accuracy achieved for women stimulated with r-hFSH & r-hLH was 88%

Posted on
July 2025

Fertiga teams up with Fertilab Barcelona in AURORA-Donor study

Suppressing the pituitary gland is essential during ovarian stimulation. Traditionally done via daily GnRH-antagonist injections, this study compared that approach to an alternative: using oral progesterone (Medroxyprogesterone). The key takeaways from the AURORA-Donor study so far:

  1. Both protocols are equally effective in egg maturation, fertilization, blastocyst development, and genetic quality (euploidy).
  2. No significant difference in hormonal levels or stimulation duration, but the progesterone protocol is:
  • 💰 40x more cost-efficient
  • 💊 More patient-friendly (oral vs. daily injections)
  • 🧑‍⚕️ Easier for clinics to manage.

The next step? Exploring gene expression in cumulus cells to better predict outcomes like live birth – stay tuned for more from the AURORA-Donor study!

Posted on
LinkedIn Post 1
May 2025

All eyes on Fertiga in EMD Serono Corporate Accelerator!

We’re thrilled to share that Fertiga has been selected to pitch at Women’s Health Week (previously SiS) in New York 2025 as part of the EMD Serono Corporate Accelerator (ESCA)! It’s an honour to join a select group of innovators driving change in reproductive health, with the support of EMD Serono, Inc. and M Ventures.


Posted on
LinkedIn Post 1
April 2025

All eyes on Fertiga in Women’s Health during BioTrinity 2025!!

We are proud to present our innovative fertility tests at the ‘Women’s Health’ Spotlight during BioTrinity 2025 in London, UK.

BioTrinity is an event organised by OBN (UK) Ltd, that brings together the life science community, and we are proud to attend and showcase Fertiga’s innovative Aurora Test. This is a fantastic opportunity to connect, collaborate, and explore new business opportunities in the UK.

Posted on
LinkedIn Post 1
November 2024

Fertiga presenting at ESHRE SIG Embryology Workshop!

Discover cutting-edge advancements in IVF technology, including non-invasive PGT-A, automatic vitrification, and AI-driven gamete and embryo selection at the ESHRE SIG Embryology Campus Event in Manchester, UK from 14-16 November 2024.

Don’t miss Tom Adriaenssens from Fertiga leading a hands-on session on ‘Non-invasive pregnancy prediction based on cumulus cells (AURORA-Test) in routine ART: The practical application, impact and challenges’.

Posted on
LinkedIn Post 1
February 2024

We have been published in PLOS One!

Can we use a method that “scores” eggs based on the cells surrounding them (called cumulus cells) to pick the ones most likely to lead to a successful pregnancy? This approach can help reduce the number of embryos we need to grow in the lab and limit extra embryos being frozen.

In countries where freezing embryos is restricted, analyzing these surrounding cells allows us to focus only on the eggs with the best potential. This can reduce the chance of twins, lower the lab workload, and improve overall success rates, because less promising eggs are not processed unnecessarily.

💡Learn how our Aurora Test on cumulus cells can revolutionize embryo generation in countries with legal restrictions.

Posted on
LinkedIn Post 1
December 2024

We are attending Belgian Society for Reproductive Medicine 2023!!

Fertiga was present at the 50th Scientific Meeting of the Belgian Society for Reproductive Medicine BSRM-Belgium in Mons on Dec 1-2. Together we explored the latest breakthroughs and shared insights with fellow experts in the field. Inspiring discussions, valuable insights and wonderful connections were made.

Posted on
LinkedIn Post 1
December 2023

All eyes on Fertiga in HealthTech Investor Summit!

Exciting news! 🚀 Fertiga is gearing up to pitch at the Health Tech Investor Summit in Bruges from December 4th. Curious to hear our pitch? Join us in Bruges next week!

EN
EN